For the nine months ended September 30, 2026, Immunocore reported total revenue of $324.8 million, a 10% increase over the prior year, and a significantly narrowed net loss of $2.1 million compared to $5.5 million in 2025. The company maintained a strong liquidity position with $901.3 million in cash, cash equivalents, and marketable securities.
Immunocore reported Q3 2026 financial results with KIMMTRAK net revenues of $102.2 million and a net loss of $14.2 million. The company highlighted the completion of target enrollment for its Phase 3 TEBE-AM trial in cutaneous melanoma and the first patient dosed in its autoimmune program for type 1 diabetes.
Term
Q3 2026
“Nearly five years after launch, KIMMTRAK remains the proven standard of care in HLA-A*02:01+ metastatic uveal melanoma. With TEBE-AM fully enrolled and data expected in the second quarter of 2027, we are advancing our mission to bring this therapy to even more patients.”
Bahija Jallal, CEO of Immunocore
“Recently, our platform delivered two significant firsts: what we believe is the first data demonstrating clinical activity and a manageable safety profile with the combination of two T cell engagers in a solid tumor, and the first patient dosed in our tissue-specific autoimmune program for type 1 diabetes.”